Emletra tablet which exhibits anti-retroviral property. Emletra tablet is a which contain combination of Lopinavir 200mg and Ritonavir 50mg Both peak active ingredients consist of anti-viral activity against human immunodeficiency virus (HIV) which is required for causing AIDS Emletra is preventing the progression of HIV virus from multiplication. Emletra tablet is used to reduce problem related to AIDS, it is not cure or prevent the disease. Emletra combination helps to postpone the symptoms caused by HIV/AIDS.

Lopinavir and Ritonavir


200mg & 50mg


Emletra indication

Emletra is primarily indicated for; HIV infection associated AIDS Normally, Emletra is used as combination with other anti-retroviral medicines.

Emletra is used to suppress the progression of HIV virus in immune cells and increase T cell counts. The number of Lopinavir blockade associated substitutions affects the virologic action of Emletra

Mechanism of action

Emletra is an anti-viral medicine that has two prime compounds which are inhibitors of HIV protease and effective against retrovirus. Retrovirus has capable of converting RNA into DNA with the help of reverse transcriptase enzyme.

Then the viral DNA incorporated into DNA of affected immune cells and then multiplied Anti-viral activity of Emletra is exhibited by Lopinavir; it is a virulent protease inhibitor which inhibits the separation of Gag-Pol polyprotein.

Gag-Pol polyprotein is most important protein in the augmentation of active virus. This viral protease enzyme breaks the Gag-Pol polyprotein at the last stage of multiplication, an active and grown virus released into infected immune cells. A Emletra tablet prohibits the proteases enzyme that leads to formation of premature, non-infectious viral particles.


After oral administration, ritonavir present in Emletra tablet inhibits the metabolism of Lopinavir; therefore, the plasma level of Lopinavir is elevated. The peak plasma concentration of the Lopinavir occurs only at 4 hours after administration The effect of food, there is no significant difference between fasted and fed condition. Emletra should be taken with or without food.

The drug Lopinavir is highly bound to the human plasma protein around 98-99%.

Lopinavir is undergoes oxidative metabolism, it is metabolized by CYP3A isoenzymes. Ritonavir is a potent CYP3A inhibitor, prohibits metabolism of Lopinavir and increased the plasma level of Lopinavir.

Emletra is highly excreted through urine and feces. Lopinavir is a potent protease inhibitor which is responsible for anti-viral activity. The terminal half-life period is approximately 2.33 hours in case of twice daily, 2.44 hours at once daily.


Brand Emletra
Ingredients Lopinavir and Ritonavir
Strength 200mg & 50mg
Manufactured Emcure

Emletra Dosage and administration

Emletra tablet should be taken with or without food. Emletra is available in fixed dose combination (Lopinavir 200mg + ritonavir 50mg)

In adults

Emletra 400mg/100mg should be given as 200mg/50mg as two tablets two times a day Emletra 800mg/200mg should be taken as 200mg/50mg as four tablets once a day. Emletra should not administered as a single dose, in case of combination with carbamazepine, Phenobarbital, or phenytoin.

Combinational therapy:
Emletra should be combined with some other anti-viral medicines; Efavirenz Nevirapine Nelfinavir By combining with the above mentioned anti-viral medicines, the prescribed dose of Emletra is 500mg/125mg, it is taken as 200mg/50mg as two tablets & 100mg/25mg as one tablet at two times a day in concomitant with efavirenz, nevirapine, Nelfinavir

In pediatric

The dose of Emletra in children is recommended on the basis of; Body weight or Body surface area (BSA) Emletra is not given as single dose for pediatric patients who are under the age of <18 years

Emletra not combined with efavirenz, nevirapine, Nelfinavir

15kg to 25kg: The BSA should be ≥0.6 to <0.9, the prescribed dose of Emletra 100mg/25mg as two tablets two times a day
>25kg to 35kg: BSA- ≥0.9 to <1.4, the recommended dose of Emletra 100mg/25mg as three tablets two times a day
>35kg: BSA ≥1.4, the dose should be taken as Emletra 100mg/25mg tablets as four tablets or two Emletra 200mg/50mg tablets.

Emletra combined with efavirenz, nevirapine, Nelfinavir

15kg to 20kg: The BSA should be ≥0.6 to <0.8, the prescribed dose of Emletra 100mg/25mg as two tablets two times a day
>20kg to 30kg: BSA- ≥0.8 to <1.2, the recommended dose of Emletra 100mg/25mg as three tablets two times a day
>30kg to 45kg: BSA ≥1.2 to <1.7, the dose should be taken as Emletra 100mg/25mg tablets as four tablets or two Emletra 200mg/50mg tablets.
>45kg: BSA ≥1.7, Emletra 100mg/25mg taken as 5 tablets at twice daily

Blood and lymphatic system

Anemia, leucopenia, neutropenia, lymphadenopathy

Cardiac problems

Atherosclerosis such as myocardial infarction, atrioventricular block

Ear and labyrinth problems

Vertigo, tinnitus




Visual impairment


Diarrhea, nausea, vomiting, abdominal pain, gastroenteritis, colitis, dyspepsia, pancreatitis, ulcers, dry mouth


Fatigue, asthenia

Hepatic disorders

AST, ALT and GGT elevation, hepatomegaly, cholangitis, hepatic steatosis

Immuno disorders

Hypersensitivity reaction like; urticaria and angioedema

Infections and infestation

Upper and lower respiratory tract infection, cellulitis, folliculitis and furuncle


Hypercholesterolemia, hyper triglycerides, weight decreased, loss of appetite


Arthralgia, back pain, Myalgia, rhabdomyolysis

Nerve disorders

Headache, insomnia, neuropathy, ageusia, convulsions


Renal failure, Hematuria, nephritis


Erectile dysfunction, amenorrhea, menorrhagia


Rashes, seborrheic dermatitis, night sweats, Pruritus, alopecia, capillaritis, vasculitis

Emletra precautions and warning

Drug interaction-CYP3A enzyme prohibition, causes increased plasma concentration of concurrent used drugs. Avoid the concomitant use. Toxicity occurs to neonates, potential risk may occur while using Emletra in neonates. Take alcohol & propylene glycol from all the drugs should be given to infants for reducing the toxicity associated to the components.


Elevation of triglyceride levels may leads to cause pancreatitis. Pancreatitis is the major risk factor during the Emletra treatment. Lipase and amylase value should be monitored periodically.

Liver toxicity

Due to elevation of AST, ALT & bilirubin, leads to cause liver injury this may concluds as liver damage or failure.

Caution should be taken

Pregnancy women, Breastfeeding, Hepatic impairment, Geriatric patients

Emletra drug interaction

Some of the medicines involved in drug interaction while taking with Emletra ; HIV-1 proteases inhibitors like Fosamprenavir/ritonavir, Indinavir, Nelfinavir (should not administered as a single dose with Emletra), ritonavir, saquinavir, tipranavir

Non-nucleoside reverse transcriptase inhibitors: efavirenz, nevirapine, delaveridine Nucleoside reverse transcriptase inhibitor: tenofovir, abacavir, zidovudine Amiodarone, lidocaine, quinidine, vincristine, vinblastine, dasatinib, nilotinib, rivaroxaban, etc

Emletra contraindications

Emletra is concomitant with potent CYP3A inducers; it leads to contraindicated causes depletion of plasma concentration of Lopinavir that leads to loss of virologic response .

Emletra is contraindicated to any active ingredients that present in Emletra tablet; Produce anaphylactic reactions like toxic epidermal necrolysis, Stevens-Johnson syndrome, Erythema multiforme, urticaria, angioedema etc.

Pregnancy category: C Emletra is not recommended for pregnancy women or who become pregnant. Emletra cause harm to unborn babies To avoid risk of infection, Emletra is not given to breastfeeding mothers.

The Storage condition of Emletra should between 20°C – 25°C (68°F-77°F). Emletra should be keep away from moisture, heat, and light

If patient fail to take tablet Emletra , it should be taken within a time. Dose should be skipped, and follow the next dose schedule Do not double the dose


Quick Contact

Prescription upload


Blueberrypharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Blueberrypharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Blueberrypharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Blueberrypharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Blueberrypharma.com

At Blueberrypharma.com , a Caregiver can order prescription medicines on your behalf.